Digitoxin sensitizes glioma cells to TRAIL-mediated apoptosis by upregulation of death receptor 5 and downregulation of survivin

Anti-Cancer Drugs

Volumn 25, Issue 1, 2014, Pages 44-52

  Lee, Dae Hee ^a   Lee, Chang Sup ^b   Kim, Dong Wook ^b   Ae, Jeh Eun ^c   Lee, Tae Hwa ^c  

^a UNIVERSITY OF COLORADO ANSCHUTZ MEDICAL CAMPUS   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c Kosin University   (South Korea)

Author keywords

Death receptor 5; Digitoxin; Glioma; Survivin; Tumor necrosis factor related apoptosis inducing ligand

Indexed keywords

DEATH RECEPTOR 5; DIGITOXIN; PROTEASOME; RECOBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; RECOMBINANT PROTEIN; SMALL INTERFERING RNA; SURVIVIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ASTROCYTE; CELL VIABILITY; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG MEGADOSE; DRUG SENSITIVITY; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; MEDIATOR; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; REDUCTION; TUMOR CELL LINE;

APOPTOSIS; BRAIN NEOPLASMS; CASPASES, EFFECTOR; CASPASES, INITIATOR; CELL LINE, TUMOR; DIGITOXIN; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; GLIOBLASTOMA; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RNA, SMALL INTERFERING; TNF-RELATED APOPTOSIS-INDUCING LIGAND; UP-REGULATION;

EID: 84889240620     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0000000000000015     Document Type: Article

References (32)

1. Fuller GN. The WHO classification of tumours of the central nervous system, 4th edition. Arch Pathol Lab Med 2008; 132:906. (Pubitemid 351918693)
2. Lee DH, Rhee JG, Lee YJ. Reactive oxygen species up-regulate p53 and Puma; a possible mechanism for apoptosis during combined treatment with TRAIL and wogonin. Br J Pharmacol 2009; 157:1189-1202.
3. Lee DH, Szczepanski MJ, Lee YJ. Magnolol induces apoptosis via inhibiting the EGFR/PI3K/Akt signaling pathway in human prostate cancer cells. J Cell Biochem 2009; 106:1113-1122.
4. Shrotriya S, Gagan D, Ramasamy K, Raina K, Barbakadze V, Merlani M, et al. Poly[3-(3, 4-dihydroxyphenyl) glyceric acid] from comfrey exerts anti-cancer efficacy against human prostate cancer via targeting androgen receptor, cell cycle arrest and apoptosis. Carcinogenesis 2012; 33:1572-1580.
5. Aggarwal BB. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 2003; 3:745-756. (Pubitemid 41070815)
6. Bellail AC, Tse MC, Song JH, Phuphanich S, Olson JJ, Sun SY, Hao C. DR5-mediated DISC controls caspase-8 cleavage and initiation of apoptosis in human glioblastomas. J Cell Mol Med 2010; 14:1303-1317.
7. Krakstad C, Chekenya M. Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics. Mol Cancer 2010; 9:135.
8. Lopez-Lazaro M. Digitoxin as an anticancer agent with selectivity for cancer cells: possible mechanisms involved. Expert Opin Ther Targets 2007; 11:1043-1053. (Pubitemid 47232620)
9. Newman RA, Yang P, Pawlus AD, Block KI. Cardiac glycosides as novel cancer therapeutic agents. Mol Interv 2008; 8:36-49. (Pubitemid 351398451)
10. Prassas I, Karagiannis GS, Batruch I, Dimitromanolakis A, Datti A, Diamandis EP. Digitoxin-induced cytotoxicity in cancer cells is mediated through distinct kinase and interferon signaling networks. Mol Cancer Ther 2011; 10:2083-2093.
11. Einbond LS, Wu HA, Su T, Chang T, Panjikaran M, Wang X, Goldsberry S. Digitoxin activates EGR1 and synergizes with paclitaxel on human breast cancer cells. J Carcinog 2010; 9:10.
12. Stolfi C, Caruso R, Franze E, Rizzo A, Rotondi A, Monteleone I, et al. 2-Methoxy-5-amino-N-hydroxybenzamide sensitizes colon cancer cells to TRAIL-induced apoptosis by regulating death receptor 5 and survivin expression. Mol Cancer Ther 2011; 10:1969-1981.
13. Kim JY, Kim EH, Kim SU, Kwon TK, Choi KS. Capsaicin sensitizes malignant glioma cells to TRAIL-mediated apoptosis via DR5 upregulation and survivin downregulation. Carcinogenesis 2010; 31:367-375.
14. Du YW, Chen JG, Bai HL, Huang HY, Wang J, Li SL, et al. A novel agonistic anti-human death receptor 5 monoclonal antibody with tumoricidal activity induces caspase- and mitochondrial-dependent apoptosis in human leukemia Jurkat cells. Cancer Biother Radiopharm 2011; 26: 143-152.
15. Noguchi K, Kawahara H, Kaji A, Katayama K, Mitsuhashi J, Sugimoto Y. Substrate-dependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib. Cancer Sci 2009; 100:1701-1707.
16. Siegel-Lakhai WS, Beijnen JH, Schellens JH. Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva) and gefitinib (Iressa). Oncologist 2005; 10:579-589. (Pubitemid 41429121)
17. Pitter KL, Galban CJ, Galban S, Tehrani OS, Li F, Charles N, et al. Perifosine and CCI 779 co-operate to induce cell death and decrease proliferation in PTEN-intact and PTEN-deficient PDGF-driven murine glioblastoma. PLoS One 2011; 6:e14545.
18. Sun W, Modak S. Emerging treatment options for the treatment of neuroblastoma: potential role of perifosine. Onco Targets Ther 2012; 5:21-29.
19. Balyasnikova IV, Ferguson SD, Han Y, Liu F, Lesniak MS. Therapeutic effect of neural stem cells expressing TRAIL and bortezomib in mice with glioma xenografts. Cancer Lett 2011; 310:148-159.
20. Kim SM, Oh JH, Park SA, Ryu CH, Lim JY, Kim DS, et al. Irradiation enhances the tumor tropism and therapeutic potential of tumor necrosis factor-related apoptosis-inducing ligand-secreting human umbilical cord blood-derived mesenchymal stem cells in glioma therapy. Stem Cells 2010; 28:2217-2228.
21. Hingtgen S, Ren X, Terwilliger E, Classon M, Weissleder R, Shah K. Targeting multiple pathways in gliomas with stem cell and viral delivered S-TRAIL and temozolomide. Mol Cancer Ther 2008; 7:3575-3585.
22. Taniguchi H, Horinaka M, Yoshida T, Yano K, Goda AE, Yasuda S, et al. Targeting the glyoxalase pathway enhances TRAIL efficacy in cancer cells by downregulating the expression of antiapoptotic molecules. Mol Cancer Ther 2012; 11:2294-2300.
23. Sung B, Park B, Yadav VR, Aggarwal BB. Celastrol, a triterpene, enhances TRAIL-induced apoptosis through the down-regulation of cell survival proteins and up-regulation of death receptors. J Biol Chem 2010; 285:11498-11507.
24. Tomicic MT, Christmann M, Kaina B. Topotecan triggers apoptosis in p53- deficient cells by forcing degradation of XIAP and survivin thereby activating caspase-3-mediated Bid cleavage. J Pharmacol Exp Ther 2010; 332:316-325.
25. Wang P, Zhen H, Zhang J, Zhang W, Zhang R, Cheng X, et al. Survivin promotes glioma angiogenesis through vascular endothelial growth factor and basic fibroblast growth factor in vitro and in vivo. Mol Carcinog 2012; 51:586-595.
26. Mellai M, Caldera V, Patrucco A, Annovazzi L, Schiffer D. Survivin expression in glioblastomas correlates with proliferation, but not with apoptosis. Anticancer Res 2008; 28:109-118. (Pubitemid 351362888)
27. Tang SY, Zhong MZ, Yuan GJ, Hou SP, Yin LL, Jiang H, Yu Z. Casticin, a flavonoid, potentiates TRAIL-induced apoptosis through modulation of anti-apoptotic proteins and death receptor 5 in colon cancer cells. Oncol Rep 2013; 29:474-480.
28. Jacquemin G, Granci V, Gallouet AS, Lalaoui N, Morle A, Iessi E. Quercetin-mediated Mcl-1 and survivin downregulation restores TRAILinduced apoptosis in non-Hodgkin's lymphoma B cells. Haematologica 2012; 97:38-46.
29. Zhao J, Tenev T, Martins LM, Downward J, Lemoine NR. The ubiquitinproteasome pathway regulates survivin degradation in a cell cycledependent manner. J Cell Sci 2000; 113 (Pt 23):4363-4371. (Pubitemid 32000697)
30. Arora V, Cheung HH, Plenchette S, Micali OC, Liston P, Korneluk RG. Degradation of survivin by the X-linked inhibitor of apoptosis (XIAP)-XAF1 complex. J Biol Chem 2007; 282:26202-26209. (Pubitemid 47443768)
31. Siegelin MD, Reuss DE, Habel A, Rami A, von Deimling A. Quercetin promotes degradation of survivin and thereby enhances death-receptormediated apoptosis in glioma cells. Neuro Oncol 2009; 11:122-131.
32. Elbaz HA, Stueckle TA, Tse W, Rojanasakul Y, Dinu CZ. Digitoxin and its analogs as novel cancer therapeutics. Exp Hematol Oncol 2012; 1:4.